WO2001070173A3 - Immunokine composition and method - Google Patents

Immunokine composition and method Download PDF

Info

Publication number
WO2001070173A3
WO2001070173A3 PCT/US2001/008150 US0108150W WO0170173A3 WO 2001070173 A3 WO2001070173 A3 WO 2001070173A3 US 0108150 W US0108150 W US 0108150W WO 0170173 A3 WO0170173 A3 WO 0170173A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunokine
bioactive polypeptide
inactivated
composition
cobratoxin
Prior art date
Application number
PCT/US2001/008150
Other languages
French (fr)
Other versions
WO2001070173A2 (en
Inventor
David D Mundschenk
Paul F Reid
Original Assignee
Phylomed Corp
David D Mundschenk
Paul F Reid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phylomed Corp, David D Mundschenk, Paul F Reid filed Critical Phylomed Corp
Priority to CA002404078A priority Critical patent/CA2404078A1/en
Priority to EP01922384A priority patent/EP1272512A4/en
Priority to AU2001249194A priority patent/AU2001249194A1/en
Publication of WO2001070173A2 publication Critical patent/WO2001070173A2/en
Publication of WO2001070173A3 publication Critical patent/WO2001070173A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

A composition and method for preventing HIV infection of mammalian cells. One aspect of the invention relates to an anti-immunodeficiency virus immunokine capable of binding to a cellular protein in a manner that prevents HIV infection of that cell. The compositions can include either an active bioactive polypeptide, such as native cobratoxin, and/or an inactivated bioactive polypeptide, such as cobratoxin in which one or more of the native disulfide bridges have been prevented from forming. The term 'immunokine' is used to refer to an inactivated bioactive polypeptide, whether inactivated by chemical, genetic, and/or synthetic means as described herein, with the proviso that a corresponding active bioactive polypeptide can be included where applicable (e.g., for in vitro use).
PCT/US2001/008150 2000-03-23 2001-03-14 Immunokine composition and method WO2001070173A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002404078A CA2404078A1 (en) 2000-03-23 2001-03-14 Immunokine composition and method
EP01922384A EP1272512A4 (en) 2000-03-23 2001-03-14 Immunokine composition and method
AU2001249194A AU2001249194A1 (en) 2000-03-23 2001-03-14 Immunokine composition and method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53345400A 2000-03-23 2000-03-23
US09/533,454 2000-03-23

Publications (2)

Publication Number Publication Date
WO2001070173A2 WO2001070173A2 (en) 2001-09-27
WO2001070173A3 true WO2001070173A3 (en) 2002-03-14

Family

ID=24126023

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/008150 WO2001070173A2 (en) 2000-03-23 2001-03-14 Immunokine composition and method

Country Status (4)

Country Link
EP (1) EP1272512A4 (en)
AU (1) AU2001249194A1 (en)
CA (1) CA2404078A1 (en)
WO (1) WO2001070173A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009540842A (en) * 2006-07-03 2009-11-26 イナゲン エイピーエス Immunotoxins for the treatment of diseases associated with CMV infection
US7259237B1 (en) 2006-12-29 2007-08-21 Miller Kent D Pan-antiviral peptides
US9220743B2 (en) 2010-01-22 2015-12-29 Nuovo Biologics, Llc Pan-antiviral peptides for protein kinase inhibition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989857A (en) * 1996-05-10 1999-11-23 Phylomed Corporation Polypeptide compositions and methods
US5994515A (en) * 1996-06-25 1999-11-30 Trustees Of The University Of Pennsylvania Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028258A1 (en) * 1996-01-30 1997-08-07 The National Institutes Of Health Cells expressing both human cd4 and cxcr4
FR2751658B1 (en) * 1996-07-26 1998-10-02 Pasteur Institut USE OF A LIGAND CHEMOKINE (SDF-1) FOR LESTR / FUSIN / CXCR4 RECEPTOR TO PREVENT OR TREAT INFECTION WITH HIV-LIKE VIRUSES
IT1291353B1 (en) * 1997-05-12 1999-01-07 San Raffaele Centro Fond PEPTIDES WITH ANTIVIRAL ACTIVITY

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989857A (en) * 1996-05-10 1999-11-23 Phylomed Corporation Polypeptide compositions and methods
US5994515A (en) * 1996-06-25 1999-11-30 Trustees Of The University Of Pennsylvania Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LEHNER ET AL.: "A rational basis for mucosal vaccination against HIV infection", IMMUNOL. REV., vol. 170, August 1999 (1999-08-01), pages 183 - 196, ISSN: 0105-2896, XP002946041 *
See also references of EP1272512A4 *
SUNTHORNANDH ET AL.: "Preparation, characterization and immunogenicity of various polymers and conjugates of elapid postsynaptic neurotoxins", MOL. IMMUNOL., vol. 29, no. 4, April 1992 (1992-04-01), pages 501 - 510, XP002946040 *

Also Published As

Publication number Publication date
CA2404078A1 (en) 2001-09-27
EP1272512A2 (en) 2003-01-08
WO2001070173A2 (en) 2001-09-27
AU2001249194A1 (en) 2001-10-03
EP1272512A4 (en) 2003-05-07

Similar Documents

Publication Publication Date Title
MY131553A (en) Lyophilized formulation of polyethylene oxide modified proteins with increased self-life
WO2003020756A3 (en) Hybrid and tandem expression of neisserial proteins
JP2002534119A5 (en)
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
DE69635609D1 (en) NUCLEIC ACID COMPOSITION, MANUFACTURE AND USE
AU9174398A (en) Peptides
WO2001044286A3 (en) Five-helix protein
AU681705B2 (en) Endosomolytically active particles
WO2003020932A1 (en) Novel secretory proteins and dna thereof
MXPA03002218A (en) Antimicrobial peptides and methods of use.
WO2001075087A3 (en) Subtilisin variants
CO5300417A1 (en) TOXIC POLYPEPTIDE COMPOSITIONS FOR ANTONOMUS INSECTS, AND METHODS OF USE
WO2002024883A3 (en) Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions
AU3855297A (en) Pharmaceutical composition for treating papillomavirus tumours and infection
NZ518999A (en) Vaccine compositions
DE69900756T2 (en) USE OF HMG PROTEINS FOR THE PRODUCTION OF MEDICINAL PRODUCTS WITH A CYTOTOXIC EFFECT
WO2001070173A3 (en) Immunokine composition and method
AU4653301A (en) Anti-freeze proteins, their production and use
RU2336279C2 (en) PROTEIN IFNAB-BPI, ITS PRECURSOR, DNA MOLECULE, EXPRESSION VECTOR, METHOD OF PRODUCTION, PHARMACEUTICAL COMPOSITION FOR INHIBITING IFN-α OR IFN-β ACTIVITY
DK1074264T3 (en) Inhibitors of neovascularization
WO2000066743A3 (en) Viral expression vectors
WO2003097677A3 (en) Novel peptide compositions and the use thereof, in particular, in the preparation of active pharmaceutical compositions against the hepatitis c virus
WO2002014345A3 (en) Antimicrobial peptides isolated from mast cells
DK0828004T3 (en) Protein disulfide isomerase gene derived from strain of methylotrophic yeast
WO2003016505A3 (en) Kgf polypeptide compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2404078

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001922384

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001922384

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001922384

Country of ref document: EP